$KSI.TSX $KSIOF Kneat reported record revenue for the first quarter of 2026, with:
- revenue up 22% year over year
- gross profit up 28% year over year
- and annual recurring revenue up 20% year over year.
Kneat's first quarter was characterized by consistent execution, as we continued to add strategic customers and were again recognized by G2 Software Review as the Leader in G2's Grid Report for Pharma and Biotech Software. The momentum has continued since the quarter closed, as we announced another strategic win, released the findings of our comprehensive annual State of Validation study (which indicates much digitalization remains to be done), and connected with scores of customers and prospects at our yearly VALIDATE conference in Dublin.
https://investors.kneat.com/news-releases/news-release-details/kneat-announces-record-revenue-first-quarter-2026
$KSI.TSX $KSIOF 2026 State of Validation Study Reveals Significant Headroom Remains for Further Digitization.
(13% are fully digital and paper still dominates)
https://investors.kneat.com/news-releases/news-release-details/2026-state-validation-study-reveals-significant-headroom-remains
$KSI.TSX $KSIOF KNEAT today announced that it has signed a Master Subscription Agreement with one of Europe’s largest Contract Development and Manufacturing Organizations (“CDMO”) to digitize their equipment validation processes.
https://investors.kneat.com/news-releases/news-release-details/leading-cdmo-selects-kneat-power-digital-validation
$KSI.TSX $KSIOF https://investors.kneat.com/news-releases/news-release-details/kneat-achieves-record-revenue-fourth-quarter-and-full-year-2025
Kneat closed 2025 with a record year for customer additions, which sets us up well for future expansions, a primary driver of our strong organic revenue growth.
-SaaS revenue up 29% year over year
-gross profit up 27% year over year
-and annual recurring revenue up 24% year over year.
$KSI.TSX $KSIOF kneat publication today :
Our mission remains constant: helping Life Sciences deliver therapies to patients to the highest safety standards.
Before we look ahead to 2026, we're celebrating what made 2025 unforgettable 👇
https://hubs.li/Q03YD0-z0
$KSI.TSX $KSIOF Another big partner / customer !!!
https://investors.kneat.com/news-releases/news-release-details/global-specialty-chemicals-leader-chooses-kneat-digital
$KSIOF $KSI.TSX this company is the next $VEEV. More and more biotech companies are starting to use digital validation platforms and Kneat is the good standard.
$KSI.TSX $KSIOF All of it is organic growth !
A leading global technology manufacturer has signed a Master Services Agreement with Kneat.
With over 30,000 employees across 30+ countries, this US-based maker of a range of devices will initially deploy Kneat Gx for Computer Systems Validation and Commissioning, Qualification and Validation across 18 sites within its medical and healthcare division. The win demonstrates our growing reach into life sciences applications beyond pharma.
https://investors.kneat.com/news-releases/news-release-details/global-technology-manufacturer-selects-kneat-drive-digital
$KSI.TSX $KSIOF One more big partner !!!
A leading manufacturer of equipment systems used across diverse industries, including healthcare has signed a three-year Master Services Agreement with Kneat.
The Company, headquartered in Europe, employs more than 15,000 people and markets an extensive portfolio of products in over 120 countries. Under this agreement, the Company will implement the Kneat Gx platform to digitize its equipment testing processes, enhancing delivery quality and client handover. Deployment will begin at two of its strategic European sites.
This agreement represents Kneat’s seventh strategic customer win in 2025. It follows a record-setting quarter for new customer additions, as life sciences and other industries expand their digital capabilities to drive quality, compliance, and accelerated speed to market.
https://investors.kneat.com/news-releases/news-release-details/global-equipment-manufacturer-selects-kneat
$KSI.TSX $KSIOF Another new big client !!!
Global Medical Technology Leader Selects Kneat
The Company is a division of a larger manufacturer, headquartered in Asia, that employs over 30,000 people and provides specialty technologies and medical devices in more than 160 countries worldwide. This Company will use the Kneat Gx platform initially for equipment validation.
Adoption of Kneat by the world’s largest life sciences companies, and the large-scale, multi-site deployments within them, highlight Kneat’s technical fit for the breadth of validation use cases and the strategic trust that the most demanding customers place in Kneat’s platform
https://investors.kneat.com/news-releases/news-release-details/global-medical-technology-leader-selects-kneat
$KSI.TSX $KSIOF
Kneat Announces Record Revenue for Second Quarter 2025
Second-quarter 2025 total revenue reaches $15.4 million, an increase of 32% year over year
Gross margin for the quarter ended June 30, 2025 reaches 75%
Annual Recurring Revenue (ARR)1 at June 30, 2025, grows 43% year over year to $64.8 million.
https://investors.kneat.com/news-releases/news-release-details/kneat-announces-record-revenue-second-quarter-2025
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Valuation
Trading at 5.9× sales vs its 5.9× historical median P/S.
Fair value ≈ $3.65 · price $3.62 today
Fair value · 1% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
